Advertisement

Filling in the knowledge gaps: Biosimilars awareness for retinal disease in the US and Europe

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

Re-Vana Therapeutics raises $11.9 million to advance ophthalmic technology platforms

The funding will give a boost to the development of the company's novel photo-crosslinked EyeLief, EyeLief-SD, and OcuLie biodegradable drug-delivery technologies.

Spotlight on GA: A bright future with potential treatments

Giving patients access to new treatments and information on changing their lifestyle habits could result in major steps towards minimising or even preventing geographic atrophy.

Advertisement
Advertisement